Patient
SITE012-0100
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE012 (BRA) (Dr. Kowalski)
consented 2025-12-25
Adverse events
5
Serious AEs
1
Open data queries
1
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-01 (study day 27); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 22); relationship: not assessed; serious criteria: hospitalization
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-07-22 (study day 17); relationship: NOT RELATED
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-07-14 (study day 9); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-07-07 (study day 2); relationship: not assessed
Data queries 1
AE Asthenia (grade 1) for SITE012-0100 has onset 2026-01-11, 1 d before first dose on 2026-01-12. Confirm onset date or record as pre-treatment.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.